
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co has demonstrated an optimistic financial outlook, with a projected increase in 1Q 2025 sales to $15.1 billion and earnings per share (EPS) growth to $2.09, reflecting strong operational performance. The company has also been highlighted for its robust international revenues, which exceed those of the U.S. on an ex-FX basis, emphasizing its global market strength. Furthermore, the anticipation of sustained growth from Winrevair, bolstered by favorable trial outcomes for pulmonary arterial hypertension, positions Merck for continued success in the competitive pharmaceutical landscape.
Bears say
Merck & Co. has experienced lower-than-expected volumes for its Welireg product, prompting a downward revision of US revenue estimates for the first quarter and beyond. Furthermore, the company anticipates a significant foreign exchange headwind of approximately $1.3 billion in FY25 revenue due to a 2% impact from currency fluctuations. This combination of reduced product performance and adverse currency effects raises concerns about the overall financial outlook for Merck & Co.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares